The future of acute care and prevention in headache.
Migraine is a chronic neurological disease with heterogeneous characteristics resulting in a range of symptom profiles, burden and disability. It affects nearly 12% of the adult population in Western countries and up to 22% of the Brazilian population, imposing considerable suffering as well as personal, economic and social losses. The pharmacological treatment of migraine is divided into preventive and acute treatment. A better comprehension of migraine pathophysiology, as well as the finding of novel molecular targets, has led to a growing number of upcoming therapeutic opportunities. The same is true of cluster headache, which affects only about 0.07%-0.4% of most populations. This review focuses on current and emerging agents and procedures for the treatment of migraine and cluster headache.
Krymchantowski
A V
AV
Rua Siqueira Campos 43/1002 Copacabana, Rio de Janeiro, Brazil. abouchkrym@globo.com
Rapoport
A M
AM
Jevoux
C C
CC
D000700:Analgesics / Q000138:chemical synthesis / Q000494:pharmacology* / Q000627:therapeutic use*; D001923:Brain Chemistry / Q000187:drug effects / Q000502:physiology; D015195:Drug Design; D006801:Humans; D007473:Ion Channels / Q000187:drug effects / Q000378:metabolism; D008881:Migraine Disorders / Q000188:drug therapy* / Q000503:physiopathology / Q000517:prevention & control*; D009462:Neurology / Q000639:trends*; D009480:Neuropharmacology / Q000639:trends*; D018377:Neurotransmitter Agents / Q000819:agonists* / Q000037:antagonists & inhibitors* / Q000378:metabolism; D011619:Psychotropic Drugs / Q000138:chemical synthesis / Q000494:pharmacology / Q000627:therapeutic use
D000700:Analgesics; D007473:Ion Channels; D018377:Neurotransmitter Agents; D011619:Psychotropic Drugs